---
title: "Johnson & Johnson’s Strong Q3 Performance and Strategic Initiatives Drive Buy Rating"
description: "Josh Jennings has issued a Buy rating for Johnson & Johnson, citing strong Q3 financial performance that exceeded market expectations in revenue and earnings per share. The company showed growth in it"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261116093.md"
published_at: "2025-10-14T17:15:10.000Z"
---

# Johnson & Johnson’s Strong Q3 Performance and Strategic Initiatives Drive Buy Rating

> Josh Jennings has issued a Buy rating for Johnson & Johnson, citing strong Q3 financial performance that exceeded market expectations in revenue and earnings per share. The company showed growth in its Innovative Medicine and MedTech segments, despite challenges like the loss of exclusivity for Stelara. JNJ has raised its operational sales guidance, indicating confidence in future growth, supported by strategic initiatives, including the planned separation of its orthopedics division. UBS also maintains a Buy rating with a $214 price target.

Josh Jennings has given his Buy rating due to a combination of factors, including Johnson & Johnson’s strong financial performance in the third quarter. The company exceeded market expectations with its revenue and earnings per share, showcasing robust growth in both its Innovative Medicine and MedTech segments. This performance highlights JNJ’s ability to effectively manage challenges, such as the loss of exclusivity for Stelara, while still achieving significant sales growth in other pharmaceutical areas.  
Additionally, Johnson & Johnson has increased its operational sales guidance, reflecting confidence in its future growth prospects. The company anticipates higher operational and reported sales, supported by its strategic initiatives and investments aimed at long-term growth. The planned separation of its orthopedics division is also seen as a potential catalyst for further expansion, contributing to Jennings’s positive outlook on the stock.

According to TipRanks, Jennings is a 3-star analyst with an average return of 2.5% and a 47.79% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Medtronic.

In another report released today, UBS also maintained a Buy rating on the stock with a $214.00 price target.

### Related Stocks

- [JNJ.US - Johnson & Johnson](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 强生｜10-K：2025 财年营收 942 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/275658131.md) |
| 当 AI 进入医院，“手术失误、错认器官” 等风险也随之而来 | 据美国数据，强生旗下 TruDi 系统引入 AI 后故障报告激增十倍，甚至出现 “导航误导” 致死风险；数据显示，AI 设备获批后首年召回率高达 43%，远超传统设备。然而，美国药监局 FDA 关键团队减员严重，传统监管框架在海量申请前几近 | [Link](https://longbridge.com/en/news/275537054.md) |
| 关键事实：强生在滑石粉案件中被判负有责任；已对贷款人提起 3,000 万美元的诉讼 | 宾夕法尼亚州的陪审团裁定强生公司对其滑石粉婴儿粉与癌症相关的责任，判给原告 25 万美元。该公司计划上诉，目前有超过 67,000 起类似的诉讼。Smith Law Firm 已对贷款方提起诉讼，涉及 3000 万美元的贷款，声称他们的目标 | [Link](https://longbridge.com/en/news/275986663.md) |
| 处理强生婴儿爽身粉案件的律师事务所起诉其诉讼资金提供者 | 史密斯律师事务所正在起诉其诉讼资金提供者，指控其在切断一笔 3000 万美元的贷款后涉嫌欺诈，该贷款对资助针对强生（J&J）的滑石粉相关诉讼至关重要。该事务所声称，贷款方串通欺诈，意图使其在涉及超过 70,000 起指控强生滑石粉产品导致癌 | [Link](https://longbridge.com/en/news/275952288.md) |
| 辉瑞在台湾开展新的 Elranatamab 研究，目标是收集现实世界的骨髓瘤数据 | 辉瑞公司（Pfizer Inc.，股票代码：PFE）正在台湾启动一项新的观察性研究，以评估其多发性骨髓瘤药物 elranatamab 在真实世界中的有效性。该研究旨在跟踪患者的治疗结果和治疗模式，尽管尚未开始招募参与者。此举预计将增强辉瑞的 | [Link](https://longbridge.com/en/news/276252273.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.